[Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus].
BACKGROUND
Chronic, therapy-resistant pruritus often fails to respond to standard measures so new therapeutic approaches are needed. Recently, the expression of cannabinoid receptors on cutaneous sensory nerve fibers was described, so cannabinoid agonists seem a rational therapeutic option for pruritus.


METHODS
In an open application observation 22 patients with prurigo, lichen simplex and pruritus applied an emollient cream containing N-palmitoyl ethanolamine (PEA).


RESULTS
In 14/22 patients a good antipruritic effect could be documented. The average reduction in itch was 86.4%. The therapy was well-tolerated by all patients; neither burning burn nor contact dermatitis was observed.


CONCLUSIONS
Topical cannabinoid agonists represent an new effective and well-tolerated therapy for refractory itching of various origins. Creams with a higher concentration may be even more effective with broader indications.
Ständer
S
S
Abteilung für Klinische Neurodermatologie, Klinik und Poliklinik für Hautkrankheiten, Universitätsklinikum Münster, Von-Esmarchstrasse 58, 48149 Münster. sonja.staender@uni-muenster.de
Reinhardt
H W
HW
Luger
T A
TA
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000577:Amides; D002186:Cannabinoids / Q000819:agonists*; D002908:Chronic Disease; D063388:Endocannabinoids; D004983:Ethanolamines; D005240:Feasibility Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010169:Palmitic Acids / Q000008:administration & dosage*; D011537:Pruritus / Q000175:diagnosis* / Q000188:drug therapy*; D016896:Treatment Outcome
D000577:Amides; D002186:Cannabinoids; D063388:Endocannabinoids; D004983:Ethanolamines; D010169:Palmitic Acids; C005958:palmidrol